Justin Knox1,2, Jennifer Scodes2, Katie Witkiewitz3, Henry R Kranzler4,5, Karl Mann6, Stephanie S O'Malley7, Melanie Wall1,2, Raymond Anton8, Deborah S Hasin1,2. 1. Columbia University Mailman School of Public Health, New York, New York. 2. New York State Psychiatric Institute, New York, New York. 3. Department of Psychology, University of New Mexico, Albuquerque, New Mexico. 4. Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 5. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania. 6. Department of Addictive Behavior and Addiction Medicine, Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Mannheim, Germany. 7. Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut. 8. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina.
Abstract
BACKGROUND: Reductions in World Health Organization (WHO) risk drinking levels have recently been shown to lower the risk of multiple adverse health outcomes, but prior work has not examined reductions in WHO risk drinking levels in relation to cardiovascular disease (CVD), the leading cause of death for men and women in the United States and of global mortality. This study examined associations between reductions in WHO risk drinking levels and subsequent risk for CVD. METHODS: In a US national survey, 1,058 very-high-risk and high-risk drinkers participated in Wave 1 interviews (2001 to 2002) and Wave 2 follow-ups (2004 to 2005). Self-reported CVD history that was communicated to the participant by a doctor or other healthcare professionals included arteriosclerosis, hypertension, angina, tachycardia, or myocardial infarction. We used logistic regression to estimate adjusted odds ratios (aOR) evaluating relationships between ≥2-level reductions in WHO risk drinking levels from Wave 1 to Wave 2 and the risk of Wave 2 CVD, controlling for baseline characteristics. RESULTS: Reductions of ≥2 WHO risk drinking levels were associated with significantly lower odds of CVD in individuals who at Wave 1 were very-high-risk (aOR = 0.58 [0.41 to 0.80]) or high-risk drinkers (aOR = 0.81 [0.70 to 0.94]). Interaction terms showed that this relationship varied by age. Among individuals >40 years old at Wave 1, reductions of ≥2 WHO risk drinking levels were associated with significantly lower odds of CVD among very-high-risk drinkers (aOR = 0.42 [0.28 to 0.63]) but not high-risk drinkers (p = 0.50). Among individuals ≤40 years old at Wave 1, reductions of ≥2 WHO risk drinking levels were associated with significantly lower odds of CVD among high-risk drinkers (aOR = 0.50 [0.37 to 0.69]) but not very-high-risk drinkers (p = 0.27). CONCLUSIONS: These results show that reductions in WHO risk drinking levels are associated with reduced CVD risk among very-high-risk and high-risk drinkers in the US general population, and provide further evidence that reducing high levels of drinking provides important benefit across multiple clinical domains.
BACKGROUND: Reductions in World Health Organization (WHO) risk drinking levels have recently been shown to lower the risk of multiple adverse health outcomes, but prior work has not examined reductions in WHO risk drinking levels in relation to cardiovascular disease (CVD), the leading cause of death for men and women in the United States and of global mortality. This study examined associations between reductions in WHO risk drinking levels and subsequent risk for CVD. METHODS: In a US national survey, 1,058 very-high-risk and high-risk drinkers participated in Wave 1 interviews (2001 to 2002) and Wave 2 follow-ups (2004 to 2005). Self-reported CVD history that was communicated to the participant by a doctor or other healthcare professionals included arteriosclerosis, hypertension, angina, tachycardia, or myocardial infarction. We used logistic regression to estimate adjusted odds ratios (aOR) evaluating relationships between ≥2-level reductions in WHO risk drinking levels from Wave 1 to Wave 2 and the risk of Wave 2CVD, controlling for baseline characteristics. RESULTS: Reductions of ≥2 WHO risk drinking levels were associated with significantly lower odds of CVD in individuals who at Wave 1 were very-high-risk (aOR = 0.58 [0.41 to 0.80]) or high-risk drinkers (aOR = 0.81 [0.70 to 0.94]). Interaction terms showed that this relationship varied by age. Among individuals >40 years old at Wave 1, reductions of ≥2 WHO risk drinking levels were associated with significantly lower odds of CVD among very-high-risk drinkers (aOR = 0.42 [0.28 to 0.63]) but not high-risk drinkers (p = 0.50). Among individuals ≤40 years old at Wave 1, reductions of ≥2 WHO risk drinking levels were associated with significantly lower odds of CVD among high-risk drinkers (aOR = 0.50 [0.37 to 0.69]) but not very-high-risk drinkers (p = 0.27). CONCLUSIONS: These results show that reductions in WHO risk drinking levels are associated with reduced CVD risk among very-high-risk and high-risk drinkers in the US general population, and provide further evidence that reducing high levels of drinking provides important benefit across multiple clinical domains.
Authors: Raymond F Anton; Raye Z Litten; Daniel E Falk; Joseph M Palumbo; Raymond T Bartus; Rebecca L Robinson; Henry R Kranzler; Thomas R Kosten; Roger E Meyer; Charles P O'Brien; Karl Mann; Didier Meulien Journal: Neuropsychopharmacology Date: 2011-09-07 Impact factor: 7.853
Authors: Bridget F Grant; S Patricia Chou; Tulshi D Saha; Roger P Pickering; Bradley T Kerridge; W June Ruan; Boji Huang; Jeesun Jung; Haitao Zhang; Amy Fan; Deborah S Hasin Journal: JAMA Psychiatry Date: 2017-09-01 Impact factor: 21.596
Authors: Katie Witkiewitz; Matthew R Pearson; Kevin A Hallgren; Stephen A Maisto; Corey R Roos; Megan Kirouac; Adam D Wilson; Kevin S Montes; Nick Heather Journal: Addiction Date: 2017-06-26 Impact factor: 6.526
Authors: B F Grant; R B Goldstein; S P Chou; B Huang; F S Stinson; D A Dawson; T D Saha; S M Smith; A J Pulay; R P Pickering; W J Ruan; W M Compton Journal: Mol Psychiatry Date: 2008-04-22 Impact factor: 15.992
Authors: Deborah S Hasin; Efrat Aharonovich; Barry S Zingman; Malka Stohl; Claire Walsh; Jennifer C Elliott; David S Fink; Justin Knox; Sean Durant; Raquel Menchaca; Anjali Sharma Journal: J Subst Abuse Treat Date: 2022-01-31
Authors: Emily E Hartwell; Richard Feinn; Katie Witkiewitz; Timothy Pond; Henry R Kranzler Journal: Alcohol Clin Exp Res Date: 2021-07-05 Impact factor: 3.928
Authors: Henry R Kranzler; Emily E Hartwell; Richard Feinn; Timothy Pond; Katie Witkiewitz; Joel Gelernter; Richard C Crist Journal: Drug Alcohol Depend Date: 2021-05-21 Impact factor: 4.852